-transparent.png){kind=logo}
Cytoreduction of leukemic leukocytosis by continuous flow centrifugation was used in an intermittent or intensive schedule as primary therapy for an average of sixteen months for management of fifteen patients with chronic myelogenous leukemia. The clinical responses and subsequent survival of the patients was studied. Hematologic and chemical changes related to the procedures and the multiple infusions of the sedimenting agent, hydroxyethyl starch, were also studied. This mode of primary therapy offered no survival advantages to patients. There were no adverse effects of the repeated use of the sedimenting agent observed.
Related Publications
J P Hester, and
K B McCredie, and
E J Freireich
May 1977,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
J P Hester, and
K B McCredie, and
E J Freireich
May 1977,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
J P Hester, and
K B McCredie, and
E J Freireich
December 1973,
Blood,
J P Hester, and
K B McCredie, and
E J Freireich
June 2015,
Gan to kagaku ryoho. Cancer & chemotherapy,
J P Hester, and
K B McCredie, and
E J Freireich
June 1986,
American journal of hematology,
J P Hester, and
K B McCredie, and
E J Freireich
January 2011,
Journal of clinical apheresis,
J P Hester, and
K B McCredie, and
E J Freireich
January 1997,
Oncology,
J P Hester, and
K B McCredie, and
E J Freireich
March 1994,
Blood,
J P Hester, and
K B McCredie, and
E J Freireich
June 2012,
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis,
J P Hester, and
K B McCredie, and
E J Freireich
November 1991,
American journal of hematology,
